Robin Hayes
Weight Loss Drugs Linked to Higher Risk of Eye Damage in Diabetic Patients
A large-scale Canadian study has found that use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines—widely prescribed to manage diabetes and promote weight loss—may significantly increase the risk of developing neovascular age-related macular degeneration (nAMD) among older diabetic patients. Researchers at the University of Toronto analyzed medical data for more than one million Ontario residents with diabetes and identified a cohort of 46,334 individuals, predominantly taking semaglutide (Ozempic) or, to a lesser extent, lixisenatide. Over a three-year follow-up period, those who used GLP-1 RAs for at least six months exhibited double the risk of new-onset nAMD compared with matched diabetic controls not on these medications. Risk escalated further—to more than three times higher—among patients taking the drugs for 30 months or longer.
· 10 min read



